{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:29:02Z","timestamp":1793806142924,"version":"4.6.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.cpcardiol.2022.101487","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T03:37:58Z","timestamp":1667533078000},"page":"101487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Therapy of ATTR Cardiac Amyloidosis: Current Indications"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4510-6805","authenticated-orcid":false,"given":"Daniela","family":"Di Lisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Di Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Brighina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo Ruggero","family":"Galassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Novo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2022.101487_bib0001","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101487_bib0002","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.2140","article-title":"Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101487_bib0003","doi-asserted-by":"crossref","DOI":"10.1038\/s41569-022-00683-z","article-title":"RNA-targeting and gene editing therapies for transthyretin amyloidosis","author":"Aimo","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101487_bib0004","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1177\/2047487320920756","article-title":"Management of complications of cardiac amyloidosis: 10 questions and answers","volume":"28","author":"Aimo","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101487_bib0005","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12875-020-01252-4","article-title":"Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner","volume":"21","author":"Gertz","year":"2020","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.cpcardiol.2022.101487_bib0006","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/13506129.2021.1917357","article-title":"Neurological involvement in Ile68Leu (p.Ile88Leu) ATTR amyloidosis: not only a cardiogenic mutation","volume":"28","author":"Pastorelli","year":"2021","journal-title":"Amyloid"},{"key":"10.1016\/j.cpcardiol.2022.101487_bib0007","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40119-021-00226-6","article-title":"Phenotypic differences of Glu89Gln genotype in ATTR amyloidosis from endemic loci: update from THAOS","volume":"10","author":"Gentile","year":"2021","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.cpcardiol.2022.101487_bib0008","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/clc.23434","article-title":"Diagnosis and treatment of trans-thyretin-related amyloidosis cardiomyopathy","volume":"43","author":"Teng","year":"2020","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101487_bib0009","article-title":"Effectiveness and safety of oral anticoagulants in cardiac amyloidosis: lights and shadows","author":"Di Lisi","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101487_bib0010","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/13506129.2022.2052838","article-title":"Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis","volume":"29","author":"Ando","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.cpcardiol.2022.101487_bib0011","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101487_bib0012","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101487_bib0013","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacc.2022.01.036","article-title":"Critical comparison of documents from scientific societies on cardiac amyloidosis: JACC state-of-the-art review","volume":"79","author":"Rapezzi","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101487_bib0014","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1093\/eurheartj\/ehz298","article-title":"Treatment of cardiac transthyretin amyloidosis: an update","volume":"40","author":"Emdin","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101487_bib0015","unstructured":"APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy). ClinicalTrials.gov Identifier: NCT03997383 http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03997383 (2022)."},{"key":"10.1016\/j.cpcardiol.2022.101487_bib0016","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101487_bib0017","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/jeac049","article-title":"Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis","author":"Giblin","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101487_bib0018","article-title":"Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging","author":"Chamling","year":"2022","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101487_bib0019","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/13506129.2020.1730790","article-title":"Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis","volume":"27","author":"Obici","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.cpcardiol.2022.101487_bib0020","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneurop-athy: a phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cpcardiol.2022.101487_bib0021","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101487_bib0022","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/jamacardio.2019.0849","article-title":"Association of Patisiran, an RNA interference therapeutic, with regional left ventricular myocardial strain in hereditary transthyretin amyloidosis: The APOLLO study","volume":"4","author":"Minamisawa","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101487_bib0023","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101487_bib0024","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014628062200384X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014628062200384X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:59:55Z","timestamp":1758938395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014628062200384X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S014628062200384X"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101487","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy of ATTR Cardiac Amyloidosis: Current Indications","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101487","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101487"}}